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ABSTRACT

Cadmium is an environmental contaminant that enters the body usually
through diet or cigarette smoke. Exposure to cadmium has been associated with
the development of breast cancer. Recent studies have suggested that cadmium
functions as an endocrine disruptor and mimics the actions of estrogen in breast
cancer cells by activating the receptor (ER) to promote breast cancer cell
growth. Although acute cadmium exposure is known to promote estrogen
receptor-mediated gene expression associated with growth, the consequence of
chronic cadmium exposure has been unclear. Since heavy metals are known to
bioaccumulate, it is necessary to understand and elucidate the effects of
prolonged, low-level cadmium exposure and its role in breast cancer progression.
Therefore, this study aims to investigate the chronic effects of cadmium exposure
on breast cancer progression. An MCF7 breast cancer cell line (MCF7-Cd)
chronically exposed to 10-7M CdCl2 was developed and serves as a model
system to facilitate studies on the effects of chronic cadmium exposure on breast
cancer progression. The data presented here suggest that prolonged cadmium
exposure results in the development of more aggressive cancer phenotypes
increased cell growth, migration, and invasion. Cells exposed to cadmium were
shown to express higher levels of SDF-1— a chemokine known to contribute to
cancer cell growth, migration and invasion. Results from this study demonstrated
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that the expression of SDF-1 was not only dependent on ER but also on c-jun
and c-fos, and the interactions between ER with c-jun and c-fos were
significantly increased at both the protein and transcription levels in cells
chronically exposed to cadmium. Additionally, the data showed that chronic
cadmium exposure was able to disrupt cell-cell adhesion by down-regulating Ecadherin expression, which led to relocation of active -catenin to the nucleus,
and in turn led to increased metastasis and invasion. The work presented here
provides a mechanistic link between chronic cadmium exposure, ER, and
breast carcinogenesis and demonstrates that prolonged cadmium exposure,
even at low levels, contributes to the progression of breast cancer.
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CHAPTER 1
INTRODUCTION

1.1 Breast Cancer
Breast cancer is one of the most common malignancies that occurs in
women in the United States and accounts for 1 in 4 female cancers. It is the 2nd
leading cause of cancer-related deaths in women after lung cancer (ACS 2012).
In 2011 approximately 230,480 cases of invasive breast cancer were diagnosed
compared to 57,650 in situ breast cancer cases (ACS 2011). Approximately
39,510 women and 410 men in 2012 are expected to die from breast cancer, with
the majority of the cases categorized as invasive breast cancer (ACS 2012).
Over the past several decades, the global incidence rates of breast cancer have
increased continuously, and it is estimated that approximately 1 in 8 women in
the United States will develop invasive breast cancer (ACS 2012).
Breast cancer is multi-factorial, which makes it difficult to pin-point a single
cause or target for its initiation, and complicates the ability to treat and
understand the disease (Richie and Swanson 2003, Althuis et al. 2005). Multiple
risk factors are associated with breast cancer development, both biological and
environmental. Biological risk factors include, but are not limited to, gender, age,
family history, and age of menarche and menopause. Environmental risk factors
include, but are not limited to, lifestyle habits and exposure to radiation,
carcinogens, phytoestrogens, xenoestrogens, organohalogens and pesticides.
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Epidemiological studies have shown that 90% of breast cancer cases are
environmental in origin (Lipworth 1995, Harvey and Darbre 2004, Darbre 2006).
A large number of epidemiological and experimental studies have
indicated a role for estrogens in the etiology of human breast cancer (Henderson
et al. 1982, Henderson et al. 1988, Feigelson et al. 1996, Henderson and
Feigelson 2000). This is why life-time exposures to estrogen are considered a
major risk factor in breast cancer. Estrogens are produced in the female ovaries
and play an important role in developmental processes, promoting growth and
differentiation of sex tissues and reproductive organs. There are three circulating
forms of estrogens in the body: estrone, estradiol, and estriol, with estradiol being
the major and most active form of estrogen. Estriol is produced in large quantities
by the placenta in pregnant women, and estrone is produced mainly in postmenopausal women. In addition, estrogens also play a pivotal role in brain
function, bone maintenance, and accumulation of adipose tissue (Bryne et al.
2009). Finally, there is clear evidence that estrogen exposure is a key contributor
to the development of breast cancer, partly through its ability to stimulate the
growth of mammary epithelial cells (Eliassen et al. 2006, Henderson and
Feigelson 2000, Henderson et al. 1988).

1.2 The Estrogen Receptor
The actions of estrogens in the breast are primarily mediated by two
nuclear estrogen receptors, ER and ER, and by GPR30 (GPER), a G-protein
coupled receptor found in the membrane. Estrogen receptors are part of a super
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family of nuclear hormone receptors that

function as ligand-activated

transcription factors. ER and ER are isoforms and share more than 97% and
59% homology in their DNA binding and ligand binding domains, respectively;
however, they are highly variable in their NH2-terminal transactivation AF-1
domains (Mosselman et al. 1996, Paech et al. 1997, Aquino et al. 2012). The
DNA binding domain contains well-conserved cysteine-rich regions which
tetrahedrally coordinate with zinc ions to form two zinc finger motifs. The Cterminal domain is the most complex region, both structurally and functionally. It
is responsible for receptor dimerization and ligand-specific gene transcription
mediation (Yang et al. 2008, Montano et al. 1995, Koide et al. 2007).
While ER and ER share similar ligand-dependent transactivation
functions, it appears that they play distinct roles in the development and
progression of breast cancer. Studies have suggested that ER mediates the
mitogenic actions of estrogen and ER mediates the anti-mitogenic effects
(Pettersson and Gustafsson 2001). In support of this, Pettersson et al. studied
mammary glands from ER knockout mice and compared them to mammary
glands from wild-type mice. Their results showed that the tissues in both animal
types were indistinguishable, although the mammary glands from ER knockout
mice were found to be underdeveloped when compared to wild-type ER mice.
From his results, Pettersson concluded that ER mediates mitogenic effects
(Pettersson et al. 2001). The role of ER remains unclear. Some studies suggest
that high levels of ER expression are indicative of more advanced breast cancer
tumors while other studies show that ER might play a protective role in breast
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cancer (Clarke et al. 2003, Bardin et al. 2004, Lazennec et al. 2001, HodgesGallagher et al. 2008, Jarvinen et al. 2000, Nair et al. 2012). Since ER’s role in
mediating

the

mitogenic

effects

of

estrogens

is

important

in

breast

carcinogenesis, it serves as an important prognostic marker of the disease.
GPR30 is a seven-transmembrane receptor found in the plasma
membrane and endoplasmic reticulum (Thomas et al. 2005, Filardo et al. 2006,
Revankar et al. 2005). Activation of GPR30 upon binding to estrogen leads to
rapid intracellular signaling by activation of a downstream signaling cascade,
that includes activation of epidermal growth factor (EGFR) and subsequent
increase of cyclic AMP, resulting in activation of transcriptional activity necessary
for proliferation (Filardo et al. 2000, Filardo et al. 2006, Maggiolini et al. 2004).
The role of GPR30 in breast cancer remains unclear due to contradictory
findings. GPR30 has been shown to be expressed in invasive ductal carcinomas
(Liu et al. 2009) and shown to induce breast cancer cell proliferation and
migration in vitro (Pandey et al. 2009, Madeo and Maggiolini 2010). However,
GPR30 has also been shown to be involved in apoptosis and cell cycle arrest
(Teng et al. 2008, Wang et al. 2008, Ariazi et al. 2010).
Seventy percent of primary breast cancer tumors are ER-positive, and
two-thirds of these respond to endocrine therapy utilizing anti-estrogens (i.e.
tamoxifen) (Hanstein et al. 2004, Giacinti et al. 2006). While a majority of the
ER positive breast cancers respond well to anti-estrogens, a fraction of the
treated tumors become de-sensitized, resistant to tamoxifen. These resistant
cancers are often more aggressive, and in some cases, tamoxifen treatments
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have been shown to further stimulate cancer growth (Hiscox et al. 2005, Clarke
et al. 1993).
ER has been shown to interact with a group of proteins referred to as
nuclear receptor regulators which include co-activators and co-repressors
(Benecke et al. 2000, Robyr et al. 2000, McKenna and O’Malley 2002).
Recruitment of steroid receptor co-activators is required for full transcriptional
activity of ER. Examples of coactivators include the p160 family of steroid
receptor coactivators SRC-1, SRC-2, SRC-3, and p300/CBP (Chen et al. 1997,
Han et al. 2009). Some of these co-regulators possess histone acetyltransferase
activity which contributes to chromatin remodeling and thus can lead to further
enhancement of ERα-mediated transactivator activity (Chen et al. 1997, Lu and
Danielsen 1998, Kishimoto et al. 2005). A study by Kishimoto et al. further
demonstrated the importance of co-activator recruitment for estrogen-induced
expression of SDF-1, cathepsin D (CTD) and c-myc, and their results showed
that coactivator binding is necessary for the expression of these ER targets.
Interestingly, these ERα genes (SDF-1, CTD and c-myc) are also involved in
breast cancer proliferation, invasion, and metastasis (Kishimoto et al. 2005).

1.3 Endocrine disruptors and Metalloestrogens
The development of the breast from puberty through cycles of pregnancy and
lactation is controlled by an intricate web of hormone signaling pathways (Darbre
2006). Among these hormone pathways, estrogen signaling is the major pathway
controlling the development of the mammary gland. The importance of estrogens
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in the etiology of breast cancer suggests that exposures to environmental or
man-made compounds or chemicals (i.e. endocrine disruptors)— which mimic
the effects of estrogen and alter the estrogen receptor signaling pathway— are
potential risk factors for the disease (Colborn et al. 1993). Endocrine disruptors
can be either man-made or naturally present in the environment, and some
common endocrine disruptors include pharmaceutical estrogens found in
contraceptives or hormone replacement therapy, phytoestrogens found in
soybeans, xeno-estrogens (man-made chemicals with estrogenic activity), and
metalloestrogens.

1.4 The Metalloestrogen Cadmium
Metalloestrogens are a group of heavy metals which mimic the actions of
estrogen. Metalloestrogens include heavy metals and metalloids such as
aluminum, nickel, cadmium, antimony, cobalt, copper, tin, vanadate, lead,
mercury, arsenite, barium, chromium, selenite, nitrate and uranium (GarciaMorales et al. 1994, Stoica et al. 2000a,b,c, Johnson et al. 2003, Martin et al.
2003, Darbre 2005, Choe et al. 2003, Raymond-Whish et al. 2007, Veselik et al.
2008). Exposure to some heavy metals has been associated with an increased
incidence of breast cancer development (Choe et al. 2003, Martin et al. 2003).
Of all the metalloestrogens, cadmium is the best characterized. Cadmium is
widely used in industry for the production of alloys, nickel-cadmium batteries,
fertilizers, pigments and plastic stabilizers. Occupationally, individuals are
exposed to cadmium through the production and processing of cadmium, the
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refining and use of copper and nickel, fossil fuel combustion, and the recycling of
electronic waste. Cadmium is found as a natural component of the Earth’s crust
and is present in the atmosphere; however, it is important to note that the
production and processing of cadmium adds 3-10 times more cadmium to the
atmosphere than natural sources (Irwin et al. 1997). Among non-occupationally
exposed individuals, exposure to cadmium occurs primarily from cigarette
smoke. For non-smoking, non-occupationally exposed individuals, exposure to
cadmium arises mostly from dietary sources due to the high rates of transfer of
cadmium from soils to plants (Clemens 2006, Franz et al. 2008, McLaughlin et al.
2006, Satarug et al. 2010). Therefore, exposure to cadmium occurs daily through
contaminated food, water, and air.
Once absorbed into the body, cadmium is rapidly transported to various
organs and has an estimated half-life of 15-20 years in humans (Jin et al. 1998,
Satarug et al. 2003). Heavy metals like cadmium tend to accumulate in soft
tissues of the body (Islam et al. 2007), and this accumulation often interferes with
normal physiological functions by disrupting protein folding and/or activity. The
chemical properties of cadmium allow it to combine easily with oxidized ligands,
particularly those containing sulfur, which are a major component of many
biological molecules including proteins. Additionally, due to the similar
coordination chemistry of zinc and cadmium, zinc is often displaced by cadmium
in many proteins and enzymes (Martelli et al 2006). Cadmium has also been
shown to induce chromosomal aberrations, aneuploidy, sister chromatid
exchanges, and to induce DNA strand breaks and DNA-protein crosslinks in
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mammalian cells (Seoane and Dulout 2001, Ochi and Oshawa 1985, Lin et al.
1994, Ochi and Oshawa 1983, Misra et al. 1998, Fatur et al. 2002, Liu and Jan
2000). Furthermore, cadmium has been shown to inhibit DNA repair, activate
proto-oncogenes (i.e. c-myc, c-jun, and c-fos) and genes associated with cell
proliferation (i.e. cyclin D1), and inhibit apoptosis, all of which can contribute to
the development and progression of breast cancer (Hartwig 1998, Abshire et al.
1996, Zheng et al. 1996, Shimada et al. 1998 Martelli et al. 2006, Siewit et al.
2010).

1.5 Cadmium and Breast Cancer
The International Agency for Research on Cancer and the National
Toxicology Program of the United States of America have classified cadmium as
a category I human carcinogen (IARC 1993, NTP 2011) because increasing
evidence shows both occupational and non-occupational exposure to cadmium
are associated with cancers of the lung, prostate, pancreas, kidney, liver,
stomach, and urinary bladder (Waalkes and Rehm 1994, Schwartz and Reis
2000, Pesch et al. 2000, Hu et al. 2002, Waalkes et al. 2000, Waalkes et al.
1999, Satarug et al. 2010, Akesson et al. 2008, Ursin et al. 1994). Cadmium
exposure has also been correlated with an increase in the incidence of breast
cancer (Cantor et al. 1994, Martin et al. 2003, Choe et al 2003).
Several studies have shown that cadmium has the ability to mimic biological
functions of estrogen in breast cancer cells by activating the estrogen receptor
(Martin et al. 2003, Bryne et al. 2009 Garcia-Morales et al. 1994, Stoica et al.
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2000, Johnson et al. 2003, Siewit et al. 2010). Previous work from our lab and
others has suggested that cadmium can promote breast cancer cell growth in
MCF-7 cells via ER (Siewit et al 2010, Martin et al. 2003, Garcia-Morales et al.
1994). Animal studies have suggested that cadmium can mimic the role of
estrogen in vivo and promote neoplastic growth, increase uterine weight, induce
changes in the uterine lining, and increase the density of mammary glands in rats
and mice (Johnson et al. 2003, Hofer et al. 2009, Ali et al. 2010, AlonsoGonzales et al. 2007). Collectively, these studies demonstrate that cadmium
functions as a hormone-disruptor and metalloestrogen and is an important
contributor to the development of breast cancer.
Recent studies have identified significantly higher levels of cadmium in
tumor tissues as well as in biological samples from tumor patients (Ionescu et al.
2006, Strumylaite et al. 2008, Satarug et al. 2010; Strumylaite et al. 2011).
Specifically, Strumylaite et al. measured and compared cadmium concentrations
in biological samples from patients with breast cancer and benign breast tumors
and found that patients with malignant cancer had significantly higher levels of
cadmium concentrations when compared to patients with either benign tumors or
estrogen receptor-negative cancers (Strumylaite et al. 2011), offering further
support for a possible relationship between cadmium and ER. Accumulating
evidence links exposures of environmental estrogens to an increased incidence
of cancer (Satarug et al. 2010, Akesson et al. 2008, Ursin et al. 1994, Cantor et
al. 1994).
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Most studies have only examined the effects of acute cadmium
exposures, and few studies have focused on the effects of chronic cadmium
exposure on breast cancer progression. Cancer progression is often marked by
the development of more aggressive phenotypes (Hanahan and Weinberg 2000),
and the role of chronic cadmium exposure in this process requires further
investigation. A recent study has demonstrated that chronic cadmium exposure
can transform normal breast epithelial cells, MCF10A cells, into a malignantappearing form. These exposed MCF10A cells displayed more aggressive
cancer-like characteristics, including an increased ability to grow in an
anchorage-independent manner and the ability to invade the extracellular matrix
through an increase in cellular expression of matrix metalloproteinase-9 (MMP9), an enzyme which facilitates tumor cell invasion (Bembrahim-Tallaa, et al.
2009). Furthermore, when these transformed cells were implanted in nude mice,
they formed highly aggressive tumors, further demonstrating the increased
metastatic potential of cells chronically exposed to cadmium. Understanding the
molecular mechanisms involved in the role of chronic cadmium exposure during
breast carcinogenesis should provide further insights into how chronic
environmental

exposures

may

contribute

to

disease

development

and

progression. Our lab is focused on investigating how chronic cadmium exposure
contributes to the progression of breast cancer, specifically focusing on two
genes, SDF-1 and CDH-1. Although there are studies on the relationship
between SDF-1 and CDH-1 (Rhodes et al. 2011, Wang et al. 2011) and cancer
progression, few to no studies have been done on the molecular connection
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between cadmium and SDF-1 and cadmium and CDH1 (Park et al. 2008,
Pearson and Prozialeck 2001).

1.6 SDF-1 and Breast Cancer Metastasis
Stromal derived factor-1 (SDF-1)— also known as CXCL12— is a novel
estrogen receptor-regulated gene and a mediator of mitogenic effects. It can
mimic the proliferative effects of estrogen in a dose-dependent manner in breast
and ovarian cells (Hall and Korach 2003, Kishimoto et al. 2005). SDF-1 is one of
the 40 to 50 human chemokines— small molecular weight proteins characterized
by the ability to stimulate chemotaxis (Vacari and Caux 2002). Chemokines are
considered pro-inflammatory and regulate cell trafficking and immune response
to recruit macrophages and other immune cells to sites of infection (Vacari and
Caux 2002). However, chemokines like SDF-1 have been reported to be
expressed in many tumor cell types and have a direct tumor growth effect
(Rollins 1997, Rossi and Zlontnik 2000, Vacari and Caux 2002). Additionally,
SDF-1 and the family of chemokines are involved in growth, invasion and
orchestrating events that result in primary tumor growth, invasion and metastasis
(Vicari and Caux 2002). SDF-1 can induce the production of metalloproteinases
(MMPs), enzymes which degrade the extracellular matrix to promote the invasive
behavior of breast cancer cells (Williams et al. 2010, Jezierska and Motyl 2009),
and facilitate metastasis. Metastasis occurs when a malignant cell has the ability
to detach from its original tumor and travel to distant sites to form secondary
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tumor foci. One mechanism that cancer cells can achieve this is by disrupting
cell-to-cell adhesion complexes to facilitate malignant cell detachment.

1.7 E-Cadherin and Breast Cancer Metastasis
E-cadherin,

otherwise

known

as

CDH-1,

is

a

Ca2+-dependent

transmembrane glycoprotein that plays a major role in cell-to-cell adhesion
(Pearson and Prozialeck 2001, Baranwal and Alahari 2009, Jiang and Mansel
2000). The cell-to-cell adhesion complexes are composed of E-cadherin linked to
the actin cytoskeleton through a group of molecules called catenins (i.e. catenin). -catenin, a member of the E-cadherin/-catenin complex, is not only
involved in cell signaling and transcriptional regulation but is also a regulator of
cell adhesion (Jiang and Mansel, 2000). E-cadherin a tumor suppressor protein
and is often used as a prognostic marker for breast cancer (Heimann and
Hellman 2000, Baranwal and Alahari 2009). Down-regulation of E-cadherin has
been associated with more aggressive breast cancers and poor prognosis
(Mohammadizadeh et al. 2009, Oka et al. 1993). A decrease or loss of Ecadherin expression could be due to genetic or epigenetic alterations. Genetic
inactivation of E-cadherin is due to mutations and/or loss of heterozygosity in
chromosome 16q22.1 and is reported to be associated with gastric carcinomas,
gynecologic cancers, hepatocellular carcinomas, and breast carcinomas (Natt et
al. 1989, Sato et al. 1990, Becker et al. 1994, Risinger et al. 1994, Kanai et al.
1994, Berx et al. 1995, Tsuda et al. 1990). Epigenetic inactivation of E-cadherin
can also result from DNA methylation (Yoshiura et al. 1995, Graff et al. 1995).
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Specifically, methylation of the E-cadherin promoter has been associated with
many human cancer types and often results in decreased expression of Ecadherin and subsequent progression and metastasis of the disease (Nass et al.
2000, Strathdee 2002).
In this thesis, I will discuss how chronic cadmium exposure results in the
deregulation of SDF-1 (Chapter 2) and E-cadherin (Chapter 3) and how this may
contribute to chronic cadmium-induced breast cancer progression.
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CHAPTER 2
CHRONIC CADMIUM EXPOSURE STIMULATES SDF-1 EXPRESSION IN AN
ER DEPENDENT MANNER

2.1 Introduction
The majority of breast cancers initially develop as hormone-dependent,
with estrogen receptors expressed in approximately 70% of breast cancer cases.
The estrogen receptor is part of the super family of nuclear hormone receptors
that function as ligand-gated transcription factors.

Two isoforms of the ER

exist— ER and ER. These receptors play pivotal roles in cell differentiation,
growth and homeostasis and function as molecular switches to modulate
between states of transcriptional repression and activation, depending on the
absence or presence of hormones. The two isoforms share considerable
homology in their DNA binding domains and carboxyl terminal domains but are
highly variable in their AF-1 amino terminal transactivation domains (Mosselman
et al. 1996, Paech et al. 1997).

Although both ER and ER bind to 17-

estradiol with similar affinities and recognize the same consensus estrogen
response element (ERE) in promoters of ER-regulated genes (Huang et al.
2002), their roles in breast cancer are quite different. While ER has long been
established as an important player in promoting the development and
progression of breast cancer, less is known about the role of ER in breast
cancer progression. The presence or absence of ER is a key determinant of the
prognosis of the disease as it determines whether the cancer will respond to
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hormone therapy or not. ER-positive breast cancers are often hormoneresponsive and are typically treated with antiestrogens like tamoxifen. However,
hormone-dependent breast cancer frequently progresses into more malignant
cancer phenotypes that are often hormone-independent.

In many of these

cases, ER is still present, and the role of ER in hormone refractory breast
tumorigenesis and its underlying mechanism is unclear. A potential mechanism
involves metalloestrogens: heavy metals that mimic the actions of estrogen and
function as endocrine disruptors.
As mentioned previously in Chapter 1, this study aims to further
investigate the chronic effects of cadmium exposure on breast cancer
progression. To this end, we developed a cadmium breast cancer cell line
(MCF7-Cd) by chronically exposing MCF7 cells to 10-7 M CdCl2 for over 6
months, and used it as a model system to study the effects of chronic cadmium
exposure on breast cancer progression. This study provides several lines of
evidence suggesting that prolonged cadmium exposure results in more
aggressive cancer phenotypes such as increased cell growth, migration and
invasion. These results also show that cells chronically exposed to cadmium
express higher levels of SDF-1 and that this expression is not only dependent on
ER but also on c-jun and c-fos members of the activating protein (AP)-1 family
of transcription factors. The ERα/c-jun/c-fos interactions were significantly
increased in cells chronically exposed to cadmium, with higher levels of ERcjun and c-fos occupying the SDF-1 promoter. In summary, these results suggest
that chronic cadmium exposure promotes more aggressive cancer phenotypes
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by modifying the molecular interactions of ER with c-jun and c-fos thereby
directly altering the expression of cancer-promoting genes like SDF-1.

2.2 Materials and Methods
Cell Culture
MCF7 cells were obtained from the American Type Culture Collection (ATCC,
Manassas, VA). MCF7-Cd was developed by exposing parental MCF7 cells to
10-7 M CdCl2 for over 6 months. Parental MCF7 and MCF7-Cd were maintained
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS; Hyclone, Logan, UT) and 1% penicillin and streptomycin
(P/S). Both cell lines were subcultured every 3-4 days.

Growth Assay
The MCF7 and MCF7-Cd cells were plated at a cell density of 2.0x105 cells/well
in six-well plates using hormone depleted media. Cells were counted in triplicate
manually every 2 days using a hemocytometer. Data points represent three
independent experiments.

Derivation of cadmium cell lines
To derive clonal cell lines chronically exposed to cadmium, MCF-7 cells were first
exposed to 10-7M CdCl2 for over 6 months in order to mimic chronic exposures.
Chronically exposed cells were plated on soft agar to allow single cells to
develop into colonies. Briefly, a 1% agar solution made with complete media
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(DMEM+10% FBS + 1% P/S) was used to create the bottom layer. Serial
dilutions of single cell suspensions were mixed with enough complete media to
make a 0.6% top agar that was added over the 1% bottom agar layer and
allowed to solidify for 30 minutes at room temperature followed by incubation at
37°C.

When colonies sizes reached about 100 cells or more, they were

individually removed from soft agar under aseptic conditions and resuspended in
complete media to permit further expansion.

Scratch Wound Assay
Approximately 2.0x104 cells were plated in 6-well plates and allowed to grow to
approximately 75-80% confluency in DMEM. A wound, or scratch, was created
with a 200μL micropipette tip. Cells were allowed to incubate for an additional 3
days and images of the scratch area were captured digitally.

Migration and Invasion Assay
A modified Boyden chamber assay was used to quantitatively assess the cells’
migration and invasion abilities. For the migration assay, cells were hormonedeprived, and 5.0x104 cells were seeded in the upper chamber over
polycarbonate membrane inserts and allowed to migrate toward the lower
chamber filled with DMEM+ 10% FBS+ 1% P/S. The cells were incubated for 1218 hours, fixed in formalin, and stained with crystal violet. The number of cells
that migrated to the underside of the filter was counted in triplicate.

For the

invasion assay, a CytoSelectTM Cell Invasion Assay Kit (Cell Biolabs, Inc, San
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Diego, CA) was used according to the manufacturer’s protocol. Briefly, 5.0x104
hormone-deprived cells were seeded in the upper chamber and the cells that
invaded through the matrigel were fixed, stained and counted as previously
described.

Western Blot
Cells were lysed in 1% SDS-HEPES buffer and the total protein concentration
was normalized using the Bio-Rad Dc Protein Assay kit (Bio-Rad, Hercules, CA).
Proteins were separated using SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica,
MA). Protein expression was monitored using protein-specific antibodies: -ERα
(NeoMarkers, Fremont, CA), -cyclin D1 (Santa Cruz Biotechnology, Santa Cruz,
CA),

-c-myc

(Santa

Cruz

Biotechnology),

-cyclin

A

(Santa

Cruz

Biotechnology), -cyclin E (Santa Cruz Biotechnology), -cdk2 (Santa Cruz
Biotechnology), -cdk4 (BD Transduction Laboratories, San Jose, CA), -p21
(Santa Cruz Biotechnology), -p-27 (Santa Cruz Biotechnology), -CDH1 (Santa
Cruz Biotechnology), --catenin (Cell Signaling Technology, Danvers, MA), GAPDH (Cell Signaling Technology).

SDF-1 ELISA
Cells were plated at a density of 1x105 cells per well in 6-well plates. Cell culture
media was collected after 48 hours and stromal cell-derived factor-1 (SDF-1)
levels were measured with the enzyme-linked immunosorbent assay (ELISA)
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SDF-1 kit (RayBiotech, Inc, Norcross, GA) according to the manufacturer’s
instructions. Briefly, 100μL of sample was added to 96-well plates containing
immobilized antibodies specific for human SDF-1 and allowed to incubate
overnight with shaking at 4°C. Wells were then washed and a biotinylated antihuman SDF-1 antibody was added, followed by another wash and subsequently
by the addition of HRP-conjugated streptavidin. Following a final wash,
tetramethylbenzidine (TMB) substrate for color development was added and
samples were read at 450nm after the addition of a stop solution.

siRNA Transfection
Approximately 1x105 cells/well were plated in 6 well plates and transfected with
siRNA (Santa Cruz Biotechnology) targeting either ER, c-jun or c-fos using
siRNA transfection reagents (Santa Cruz Biotechnology). A scrambled siRNA
was transfected as a control. Five hours after transfection, the medium was
changed to DMEM medium containing 10% FBS and 1% P/S.

Cells were

harvested 48 hours later for gene and/or protein expression analysis using semiquantitative reverse transcription-polymerase chain reactions (RT-PCR) or
quantitative RT-PCR (qRT-PCR), and Western blot analysis, respectively.

Reverse Transcriptase Polymerase Chain Reaction (RT- PCR)
Total RNA was isolated from cells using TRI-Reagent (Zymo Research
Corporation, Irvine, CA) and columns from the Direct-zol RNA MiniPrep kit (Zymo
Research) according to the manufacturer’s protocol. Three micrograms (g) of
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total RNA were used for the reverse transcription reaction with oligo-dT18 primers
and Moloney Murine Leukemia Reverse Transcriptase (M-MLV RT, Promega,
Madison,WI). Gene expression was monitored using semi-quantitative PCR for
28 cycles. PCR products were separated by agarose gel electrophoresis, and
visualized using Chemi-Doc (Biorad). Gene expression was quantified using
gene specific primers in a quantitative real-time RT-PCR procedure with SYBR
green (SA Biosciences, Valencia, CA). All primers were synthesized by
Integrated DNA Technologies, Inc. (IDT; San Diego, CA).
RT-PCR Primer Sequences:
SDF-1F : GTCAGCCTGAGCTACAGATGC (Boudot et al. 2011)
SDF-1R: CACTTTAGCTTCGGGTCAATG (Boudot et al. 2011)
ERF: ATGACCCTCCACACCAAAGCAT
ERR: ACTGGCCAATCTTTCTCTGCCA
c-mycF: CTCCACACATCAGCACAACT
c-mycR: GTTTCCGCAACAAGTCCTCT
cycD1F: AATGTGTGCAGAAGGAGGTC
cycD1R: GAGGGCGGATTGGAAATGAA
GAPDHF: GAAATCCCATCACCATCTTCCAG
GAPDHR: ATGAGTCCTTCCACGATACCAAAG

Coimmunoprecipitation (CoIP) Assay
Cells were plated in 10 cm tissue culture plates and harvested 48 hours later.
Cells were lysed in 0.5% NP-40 lysis buffer and sonicated three times for 30
seconds. Cell lysates were immunoprecipitated with -ER, -c-fos, -c-jun or
normal rabbit IgG (Santa Cruz Biotechnology) for 2 hours followed by incubation
with either protein A or G agarose beads for 1 hour. Protein complexes were
separated with SDS-PAGE followed by Western blot analysis with ER, c-jun, cfos, and normal rabbit IgG antibodies.
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Chromatin Immunoprecipitation (ChIP) Assay
Cells were plated in 10cm plates and harvested by fixation with formaldehyde.
Cells were lysed and sonicated in lysis buffer to fragment the chromatin into 1-2
kb fragments.

Chromatin mixtures were immunoprecipitated with antibodies

specific for ER, c-fos, and c-jun (Santa Cruz Biotechnology). Antibody
complexes were purified using protein A agarose beads (Pierce, Rockford, IL).
The complexes were reverse-cross-linked to release the chromatin fragments by
incubation at 65oC for 4-6 hours. DNA fragments were purified using QIAQuick
columns (Qiagen, Germantown, MD). Occupancy at a specific promoter was
determined with PCR using promoter specific primers.

PCR products were

detected with agarose gel electrophoresis and quantitated using Quantity One ®
(Biorad, Hercules, CA).
ChIP Primer Sequences:
SDF1-ChIPF: CACCATTGAGAGGTCGGAAG (Boudot et al. 2011)
SDF1-ChIPR: AATGAGACCCGTCTTTGCAG (Boudot et al. 2011)
cyclin D1-ChIPF: CATTCAGAGGTGTGTTTCTCCC
cyclin D1-ChIPR: CTCAGCGACTGCATCTTCTTTC
c-myc-ChIP F:GACACATCTCAGGGCTAAACAG
c-myc-ChIP R: GAGAGTGGAGGAAAGAAGGGTA
U6RNA-ChIPF: GAGGGCCTATTTCCCATGATTC
U6RNA-ChIPR :GAATTTGCGTGTCATCCTTGC

ChIP re-ChIP
For the re-ChIP assay, protein A-antibody complexes resulting from the first ChIP
assay were extracted twice after incubation with 100l of 10mM DTT for 20
minutes at 37°C. The supernatants were pooled and diluted 10 times with Re-
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Figure 1: Chronic cadmium exposure induces more aggressive cancer phenotypes: cell growth, migration and invasion. (A) MCF7-Cd
cells (black bars) and parental MCF-7 cells (white bars) were plated in 6 well plates under hormone-deprived conditions and cell growth was monitored 2, 4, and 6 days after plating by counting in triplicate. Experimental results are averages of three independent experiments (P<0.01). (B) A
scratch wound assay was used to assess cell migration ability. MCF-7 and MCF7-Cd cells were plated in 6-well plates and allowed to reach 7080% confluence. A scratch was created using a p-200 pipette tip and a digital image was captured on Day 0. Cells were then allowed to grow and
migrate for 3 days and images of the wound were captured 3 days later. (C) Modified Boyden chamber assays were performed to measure the
migration abilities of the cells. MCF7 (white bars) and MCF7-Cd (black bars) cells were seeded into upper chambers and cells were allowed to
migrate to lower chamber for 15-18 hours. Data is representative of 3 independent experiments performed in triplicate (P< 0.01). (D) An invasion
assay was performed by seeding either MCF7 (white bars) or MCF7-Cd (black bars) cells in the upper chambers. Cells were allowed to invade
through matrigel-coated membranes for 18-24 hours.Data is an average of 3 independent experiments done in triplicate (P<0.01).

ChIP Buffer (20 mM Tris- HCl, pH 8.1, 2 mM EDTA, 150 mM NaCl, and 0.1%
Triton X-100). The chromatin mixture was re-ChIPed with the second antibody:
-ER, -c-jun, -c-fos or normal rabbit IgG, (Santa Cruz Biotechnology).
Antibody complexes were purified using protein A beads, and the complexes
were reverse-cross-linked to release the chromatin fragments after an incubation
at 65oC for 4-6 hours. The DNA was purified with QIAQuick and analyzed as
previously described.

Luciferase Reporter Assay
The reporter gene assay was performed by sequentially transfecting MCF7 cells
with siRNA targeting ER (Santa Cruz Biotechnology) followed by the SDF1
promoter-Luc reporter plasmid. Five hours after siRNA transfection, the second
transfection with the SDF-1 Luc reporter plasmid along with the pRL-SV40
Renilla luciferase plasmid (Promega) was accomplished using Fugene HD
(Promega) according to the manufacturer’s protocol. The medium was changed
to DMEM media containing 10% FBS and penicillin and streptomycin, and cells
were harvested 48 hours post-transfection and analyzed using a dual luciferase
assay kit (Promega). All reporter gene assays were performed in quadruplicate,
with the entire experiment repeated at least three times. SDF-1-Luc was
purchased from Genecopoeia (Rockville, MD).

2.3 Results
We previously found that acute cadmium exposures increase growth rates
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of three ERα positive breast cancer cell lines— MCF7, T-47D and ZR-75-1— and
increases the expression of genes associated with growth (Siewit et al. 2010).
The observation that acute cadmium exposure stimulates breast cancer cell
proliferation led us to question the effects of chronic cadmium exposure on
breast cancer progression. To understand how chronic cadmium exposure
affects the progression of ER-positive breast cancer, a cell line chronically
exposed to cadmium was developed by exposing cells to low concentrations of
cadmium (10-7 M) for over six months. Since cancer progression often results in
the acquisition of more aggressive phenotypes, including an increased growth
rate (Hanahan and Weinberg 2000), the effects of prolonged cadmium exposure
on cancer cell growth was assessed. The growth properties of cells chronically
exposed to cadmium (MCF7-Cd) were analyzed in the presence or absence of
cadmium and compared to parental MCF7 cells. Approximately 2.5x10 4 cells
were plated in 6-well plates under hormone-deprived conditions and treated with
10-7 M cadmium chloride (CdCl2) or mock treated with phosphate buffered saline
(PBS). Cell growth was monitored 2, 4 and 6 days after treatment. The MCF7Cd cells displayed a significantly faster growth rate than the parental MCF7 cells
in both the presence and absence of cadmium, suggesting that cells exposed to
prolonged periods of cadmium have accelerated growth (Fig. 1A).
In addition to increased growth rates, one of the characteristics that cancer
cells acquire as they become more malignant is the ability to metastasize
(Hanahan and Weinberg 2000). This is characterized by an increased ability to
migrate and invade the extracellular matrix. Therefore, the migration ability of
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cells chronically exposed to cadmium was analyzed and compared to parental
MCF7 cells by using a scratch wound assay (Fig. 1B). Again, cells were plated in
a 6-well plate, and when cells reached 70% confluence, a wound was created
using a p200 pipette tip. Cells were rinsed with PBS and migration was observed
3 days later. The data suggest that MCF7-Cd cells display a greater migration
ability than the parental MCF7 cells (Fig. 1B).
To confirm the qualitative observations in Figure 1B, a modified Boyden
Chamber assay was used to quantify the effects of chronic cadmium exposure
on breast cancer cell migration (Fig. 1C). In this assay, 5x10 4 cells of each cell
type (MCF7 or MCF7-Cd) were plated in the upper chamber and allowed to
migrate for 16 hours through an 8µM polycarbonate membrane. Cells that have
the ability to migrate were able to attach to the underside of the membrane
whereas non-migratory cells stayed in the upper chamber. Cells on the underside
of the membrane were fixed and stained with crystal violet, and a microscope
was used to determine the number of cells migrated in each well. The results
suggest that cells chronically exposed to cadmium display an increased ability to
migrate (31 vs. 54, p < 0.05, Fig. 1C). The invasive ability of the MCF7-Cd cells
was also investigated using a similar assay, but the membranes in the chambers
were coated with matrigel in order to mimic the extracellular matrix (Fig. 1D).
Again, 5x104 cells (MCF7 or MCF7-Cd) were added to the upper chamber, and
cells with the ability to invade were able to digest the matrigel and attach to the
underside of the chamber. Cells were allowed to invade for 18 hours and then
counted as in the migration assay. Consistent with the results from the migration
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assay, MCF7-Cd cells also displayed a greater ability to digest the matrigel and
invade (48 vs 94, p < 0.05).
To understand the molecular alterations that occur in the cells exposed for
prolonged periods to cadmium, clonal cell lines (MCF7-Cd2 to Cd12) were
derived from MCF7-Cd cells, and differentially expressed genes were analyzed
using both a metastasis-specific PCR array (Superarray RT-Profiler) and
microarray. Both array studies identified SDF-1, also known as CXCL12, as
being up-regulated in a majority of the cadmium-adapted cells. Further
verification using semi-quantitative RT-PCR demonstrated that about 70% of the
cadmium adapted cell lines expressed higher levels of SDF-1 (Fig. 2A), with Cd7
and Cd12 expressing the highest levels. The levels of SDF-1 protein present in
the Cd7 and Cd12 cells and secreted into the media were also examined using
Western blot analysis and ELISA, respectively.

Consistent with the gene

expression data, levels of SDF-1 in both the protein lysates and in the media
were elevated, as shown in Figures 2B and C.
Interestingly, SDF-1 has been shown to be an estrogen receptor (ERα)
regulated gene (Hall and Korach 2003).

Since cadmium functions as a

metalloestrogen, we questioned whether cadmium could induce the expression
of SDF-1. To determine if the expression of SDF-1 is regulated by acute
cadmium exposure, parental MCF7 cells were treated with either 10 -6 M CdCl2 or
10-7 M 17-estradiol. The results in figure 3 indicate that both acute cadmium and
estrogen can increase SDF-1 expression by 6 and 12 fold, respectively (Fig. 3 AB).

Estrogen-induced SDF-1 expression continued to increase for up to 24
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Figure 2: Chronic cadmium exposed cells express and secrete higher levels of SDF-1. (A)
MCF7 and MCF7-Cd clonal derivatives (Cd-2, -4, -6, -7, -8, -11 and -12) were plated in 6 well
plates and total RNA was isolated for gene expression analysis using semi-quantitative PCR.
GAPDH was used as a loading control. (B) SDF-1 protein expression in MCF7, Cd7, and Cd12
cells was analyzed with Western blot analysis. Actin was used as a loading control. (C) Conditioned media was collected in the same experiments shown in B after 24 hours, and the levels of
SDF-1 were measured with an enzyme-linked immunosorbent assay (ELISA). Data is representative of several experiments done in triplicate (P < 0.01).
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Figure 3: SDF-1 is induced by acute cadmium and estrogen exposure. MCF7 cells were
hormone deprived and treated with either 10-7 M E2 (white bars) or 10-6 M CdCl2 (black bars).
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hours, whereas cadmium-induced SDF-1 expression peaked after 8 hours of
exposure.

Although, cadmium induction was not as robust as 17-estradiol

induction, these results clearly demonstrate that cadmium has the ability to
stimulate SDF-1 expression within hours of exposure.
Given that SDF-1 is an ER-target gene, SDF-1 expression was further
analyzed in the Cd-cell lines to see if it was dependent on ER by depleting
endogenous levels of ER (Fig. 4). To mediate ER silencing (Ei), siRNA was
transfected into parental MCF7, MCF7-Cd4,-Cd7 and -Cd12 cells, and the effects
of decreased ER levels on SDF-1 expression were examined. Cells transfected
with scrambled siRNA were used as controls (Ci). At 48 hours after transfection,
cells were collected for both protein and gene expression analyses using
Western blot and semi-quantitative RT-PCR, respectively (Fig. 4A-B). Gene
expression analysis was also confirmed by quantitative RT-PCR (qRT-PCR) (Fig.
4C). As expected, the successful depletion of ER by siRNA resulted in lower
levels of SDF-1 in parental MCF7 cells. Interestingly, a similar effect was
observed in cells chronically exposed to cadmium, suggesting that SDF-1
expression in the cadmium-adapted cells is also dependent on ER.

To

determine if ER plays a direct role in regulating the transcription of SDF-1, a
luciferase reporter assay was used in the presence and absence of ERα (Fig.
4E). MCF7, Cd7 and Cd12 cells were transfected with either a control siRNA
(Ci) or one that targets ER (Ei). The depletion of ERas shown by the Western
blot, significantly decreases the transactivation of the SDF-1 promoter in all three

40

MCF7
Ci

Ei

Cd4
Ci

Ei

Cd7
Ci

Ei

B

Cd12
Ci

Ei

Ci

SDF-1

SDF-1

CycD

CycD

c-myc

c-myc

GAPDH

GAPDH

ERα
α
Actin

si-ERα
α
MCF7
Cd7
Cd12
Ci Ei Ci Ei Ci Ei

E

Relative Knockdown

ERα
α

ERα
α

D

MCF7

Cd4

Ei

Ci

Ei

Cd7
Ci

Ei

Cd12
Ci

Ei

C
Relative Gene Fold Knock-down

A

ERα
α

5
4
3
2
1
0

MCF7

4
3

Cd4

5

8

4

6

3

2

SDF-1

Cd7

Cd12

4

2
1

2

1

0

Ci

Ei
MCF7

0

0

Ci

Ei
Cd7

Ci

Ei
Cd12

Figure 4: SDF-1 expression in cells chronically exposed to cadmium is dependent on ERα
α. MCF7, Cd4, Cd7 and Cd12 cells were plated in 6-well plates and transfected with either si-ERα (Ei) or si-control (Ci), and collected 48 hours after treatment for protein and gene
expression analyses using (A) Western blot and (B) RT-PCR, respectively. Changes in gene expression were also measured using (C) quantitative RT-PCR, and fold knockdown was expressed as CtEi/ CtCi. Fold knockdown of ERα and SDF-1 are represented in white and black,
respectively. Data is representative of at least three independent experiments done in triplicate. GAPDH was used as a control. MCF7, Cd7
and Cd12 were also transfected with siRNA targeting ERα and the transactivation of the SDF-1 promoter measured using a luciferase reporter assay. Following transfection, cells were collected for (D) Western blot analysis and (E) reporter gene assay. Data represents at least
three independent experiments done in quadruplicate. Actin was used as a loading control for the Western blot.

cell lines (Fig. 4E), further establishing the role of ER in regulating the
expression of SDF-1.
Although SDF-1 is an ER-regulated gene, it is unclear whether ER
regulates SDF-1 alone or in collaboration with other transcription factors. To
determine

if

ERinteracts

with

other

transcription

factors,

a

co-

immunoprecipitation experiment was used to identify potential transcription
factors that may interact with ER in cells chronically exposed to cadmium (Fig.
5). Cells were grown for 48 hours, and cell lysates were immunoprecipitated with
α-ERα antibodies. The presence of specific transcription factors in the
immunoprecipitated complexes was determined with Western blot analysis.
Results in figure 5A indicate that a greater fraction of c-fos and c-jun coprecipitated with ER in the Cd7 and Cd12 cells when compared to the parental
MCF7 (M) cells, whereas similar levels of Sp-1 and -catenin— two transcription
factors known to interact with ER— were found in both parental MCF7 cells and
cells chronically exposed to cadmium (Fig. 5A). Changes in the interaction of
ER with

c-jun

and

c-fos were further confirmed by reciprocal co-

immunoprecipitation with antibodies against c-jun and c-fos (Fig. 5B).
Despite the observation that ER co-precipitates with both c-jun and c-fos,
it is unclear whether these AP-1 transcription factors are directly involved in the
regulation of SDF-1. To understand the role of c-jun and c-fos in mediating the
expression of SDF-1, the expression of SDF-1 cells was analyzed following
siRNA-mediated silencing of c-jun and c-fos (Fig. 5C). MCF7, Cd7 and Cd12
cells were transfected with siRNA to target either c-jun (Ji) or c-fos (Fi), and cells
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Figure 5: Prolonged exposure to cadmium enhances the interactions of ERα
α with c-jun
and c-fos. (A) MCF7, Cd7 and Cd12 cell lysates were immunoprecipitated with either α-ERα or
normal rabbit IgG. Proteins interacting with ERα were analyzed with Western blot analysis. (B)
Reverse co-IP was performed with α-c-Jun, α-c-Fos, or normal rabbit IgG. (C) MCF7, Cd7 and
Cd12 were plated in 6-well plates and transfected with siRNA targeting either c-jun (Ji), c-fos (Fi)
or a scramble siRNA control (Ci) and collected 48 hours later for protein analysis.
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were harvested 48 hours later for Western blot analysis (Fig. 5C). While lower
levels of c-jun and c-fos resulted in a significant reduction of SDF-1 expression,
these lower levels of c-jun and c-fos apparently led to decreased levels of ER,
complicating the determination of whether c-jun and c-fos directly regulate SDF-1
expression.
Since the regulatory region of SDF-1 consists of only one full ERE site
located 234 bp upstream of the promoter, five half ERE sites located within the
proximal promoter, and multiple AP-1 and Sp-1 sites on the promoter (Boudot et
al 2011), it is probable that ER may interact with other transcription factors to
regulate SDF-1 expression. Therefore, a chromatin immunoprecipitation (ChIP)
assay was used to determine whether a greater fraction of c-jun and c-fos is
recruited to the SDF-1 promoter in cells chronically exposed to cadmium. Cells
were plated for 48 hours and harvested for ChIP analysis. The recruitment of
ERα, c-jun and c-fos was analyzed by PCR. Results in Figures 6A and B indicate
that cells chronically exposed to cadmium (Cd7 and Cd12) had higher levels of
ERα recruited to the SDF-1 promoter in comparison to parental MCF7 (M) cells
(27% and 47% vs. 15%, respectively). Similarly, the occupancy of c-jun and c-fos
on the SDF-1 promoter were significantly elevated in Cd7 and Cd12 cells when
compared to parental MCF7 cells, with c-jun showing at least a 2-fold increase
(Fig. 6A-B). The occupancy of all three transcription factors (ER, c-jun, and cfos) was also found elevated in the cyclin D1 and c-myc promoters of cells
chronically exposed to cadmium (Fig. 6A-B). In contrast, Sp-1 was only found
elevated on the c-myc promoter of cells chronically exposed to cadmium (Cd7
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Figure 6: ERα
α, c-fos and c-jun are recruited to SDF-1 promoter. (A) MCF-7, Cd7 and Cd12
cells were harvested for chromatin immunoprecititation (ChIP) analysis. ChIP analysis was
done with α-ERα, α-c-Fos, α-c-Jun, and α-Sp1, and recruitment of proteins to the SDF-1, cyclin
D1 a n d c -m yc p ro m o t e rs wa s d e t e rm in e d u s in g p ro m o t e r s p e c if ic p rim e rs a n d
semi-quantitative PCR. (B) Band intensities of PCR products for SDF-1, cycD, and c-myc were
quantified and normalized to input using Quantity One (Bio-Rad) (P<0.001). (C) In the ChIP
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(P<0.001).

45

and 12); no significant difference in Sp-1 levels was observed on the SDF-1 and
cyclin D1 promoters among the different cell lines (Fig. 6A).
While the results from the ChIP assay strongly support the notion that
ER, c-jun and c-fos all regulate SDF-1 expression, it is unclear whether these
transcription factors work independently or together as one regulatory complex.
To fully understand the components of the transcription complex regulating SDF1 expression, a ChIP re-ChIP assay was performed. Following the first ChIP
assay with either ER or rabbit IgG as a control, the DNA-protein complexes
were extracted and re-ChIPed with a second antibody (c-jun, or rabbit IgG). Data
from both forward and reverse ChIP re-ChIP assays display higher levels of
ER/c-jun complex bound to the SDF-1 promoter in Cd7 and Cd12 cells when
compared to parental MCF-7 cells (Fig. 6C). Since previous studies have
suggested that ER and c-fos do not interact directly (Teyssier et al. 2001), we
evaluated the presence of c-fos in the ER/c-jun complex using a triple-ChIP
assay (three sequential chromatin IPs), in which the re-ChIPed DNA containing
ER/c-jun complexes was immunoprecipitated with a third antibody (c-fos or
rabbit IgG) to verify the presence of c-fos in the complex. Results in Figure 6D
not only confirm the occupancy of ER/c-jun complex on the SDF-1 promoter,
but also demonstrate that c-fos is involved in transcriptional regulation of SDF-1
in both parental and cadmium-adapted cell lines.

2.4 Discussion
Often referred to as an endocrine disruptor, cadmium is an environmental
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contaminant that has been shown to have the ability to bind to the estrogen
receptor and alter the expression of various estrogen receptor target genes
(Martin et al. 2003, Garcia-Morales et al. 1994, Siewit et al. 2010, Yu et al. 2010).
While epidemiological and animal studies (Martin et al. 2003, Johnson et al.
2003, Hofer et al. 2009, Alonso-Gonzalez et al. 2007, Ali et al. 2010, Waalkes et
al. 1999, Gunn et al. 1964, Poirier et al. 1983) have implicated cadmium as a
carcinogen, there is no direct evidence suggesting cadmium promotes breast
cancer in humans.

Despite this, the International Agency for Research on

Cancer (IARC) has classified cadmium as a potential human carcinogen.
Although multiple studies— including work from this lab— have demonstrated
that acute cadmium exposures can stimulate breast cancer cell growth and can
activate the estrogen receptor to mediate the expression of genes associated
with cell growth (Stoica et al. 2000, Martin et al. 2003, Garcia-Morales et al.
1994, Choe et al. 2003, Liu et al. 2008, Brama et al. 2007), less is known about
how chronic exposures of cadmium may contribute to the development and
progression of breast cancer. Studies on prostate cancer and sarcomas have
indicated that chronic exposures to cadmium can be associated with more
malignant tumors (Waalkes et al. 2000, Achanzar et al. 2001, Haga et al. 1996).
Additionally, significantly higher levels of cadmium have been found in breast
tumor tissues in comparison to non-tumor tissues (Antila et al. 1996, Strumylaite
et al. 2011, Strumylaite et al. 2008, Romanowicz et al. 2011, Ionescu et al.
2006). The chronic effects of cadmium on the progression of breast cancer and
the molecular alterations induced by cadmium have never before been fully
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elucidated.
Results from this study confirm that chronic cadmium exposure does
promote the development of more aggressive cancer characteristics, including
increased cell growth and an increased ability to migrate and invade (Fig. 1). To
understand the impact of chronic cadmium exposures at the molecular level,
clonal cell lines were developed from the original MCF7-Cd cell line (MCF7-Cd-2
to 12), and it was found that SDF-1, one of the genes identified in microarray
expression analysis, was elevated in more than 70% of the cadmium-adapted
cell lines (Fig. 2A). In addition to expressing higher levels of SDF-1 at the mRNA
level, cells chronically exposed to cadmium (MCF7-Cd7 and Cd12) also
expressed and secreted more SDF-1 protein into the media (Fig. 2B-C),
consistent with its function as a chemokine, a factor that promotes cell migration
and metastasis (Mukherjee et al. 2013).
Interestingly, past studies have also shown SDF-1 to be regulated by ER
(Hall and Korach 2003, Boudot et al. 2011, Zhu et al. 2006). Consistent with
these findings, SDF-1 mRNA levels were indeed shown to increase within hours
of the cells being treated with 17-estradiol (Fig. 3A-B). Strikingly, our results
demonstrate that the metalloestrogen cadmium can also stimulate SDF-1 gene
expression, but to a lesser extent than 17-estradiol (6 fold vs. 12 fold, Fig. 3).
To establish a link between chronic cadmium-induced SDF-1 expression and
ER, siRNA was used to reduce intracellular levels of ER in parental MCF7,
MCF7-Cd4, -Cd7, and -Cd12 cells. Results showed that suppressing ERα
expression subsequently inhibited the expression of SDF-1 in both MCF7 cells
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and in cells chronically exposed to cadmium, suggesting that elevated SDF-1
expression is in part dependent on ER (Fig. 4). In order to determine whether
ER regulates the transcription of the SDF-1 gene, a luciferase reporter assay
was used with SDF-1-luc and co-transfected siRNAs to silence ER. Results in
Figure 4E suggest that depletion of ER, as indicated by Western blot analysis
(Fig. 4D), significantly reduces transcriptional activation of the SDF-1 promoter.
Similarly, silencing ER in cadmium-adapted and parental MCF-7 cells also
decreased other ER target genesspecifically cyclin D1 and c-myc (Fig. 4). This
further indicates that the estrogen receptor signaling pathway is intact and may
have a heightened response in cells chronically exposed to cadmium.
To determine if chronic cadmium exposure enhances the interaction of
ER with other transcription factors, co-immunoprecipitation experiments were
performed. Results in Figure 5A show that a greater fraction of c-jun and c-fos
co-precipitated with ER in the cadmium-exposed cells. These interactions were
confirmed by reciprocal co-immunoprecipitation (co-IP) with either c-jun or c-fos
(Fig. 5B). While the interaction of ER with c-jun is well-documented (Strumylaite
et al. 2008, Romanowicz et al. 2011, Ionescu et al. 2006, Hanahan and
Weinberg 2000), the direct interaction between ER and c-fos has not been
documented. More specifically, a study by Teyssier et al. demonstrated that ER
binds directly to c-jun, but not to c-fos, in pull-down assays (Teyssier et al. 2001).
Although our co-IP results show an ER/c-fos interaction, it is important to note
that this interaction may be mediated indirectly by c-jun, especially since c-jun
and c-fos often function as heterodimers (Bjornstrom et al. 2005). Consistent with
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the results presented in this study, previous studies have demonstrated that both
cadmium and arsenic can increase the interactions of ER with c-jun under acute
exposures (Siewit et al. 2010, Qi et al. 2004).
Though promising, the increased interactions between ER, c-jun and cfos do not prove that these complexes are directly involved in regulating the
expression of SDF-1 in cells chronically exposed to cadmium. We attempted to
show this via siRNA-mediated silencing of c-jun and c-fos, which did result in a
reduction of SDF-1. Unfortunately, the data could not clearly demonstrate
whether the decrease in SDF-1 was due solely to c-jun or c-fos since the down
regulation of c-jun and c-fos also decreased ER levels, which is already known
to affect SDF-1 levels (Fig. 5C).
To confirm the roles of ER, c-jun and c-fos in the transcriptional
regulation of SDF-1 in cells chronically exposed to cadmium, chromatin
immunoprecipiation (ChIP) assays were then used to determine the occupancy
status of each transcription factor on the SDF-1 promoter. In line with previous
reports by Zhu et al. and Boudot et al., our results demonstrate that ER is
recruited to the SDF-1 promoter and furthermore, the promoter occupancy by
ERα is elevated in cells chronically exposed to cadmium (Fig. 6A-B) (Boudot et
al. 2011, Zhu et al. 2006). A greater fraction of c-jun and c-fos were also found
on the SDF-1, cyclin D1, and c-myc promoters after chronic cadmium exposure.
In contrast, the levels of transcription factor Sp-1 were only elevated on the cmyc promoter.

50

Whether ER regulates the expression of SDF-1 by binding to classical
ERE sites or via interactions with other transcription factors was uncertain.
However, based on the occupancy patterns of c-jun and c-fos on the SDF-1
promoter, it seemed conceivable that SDF-1 is regulated in a similar manner as
cyclin D1 and c-myc— both of which are regulated by the interaction of ERα with
c-jun/c-fos heterodimers (Klein et al. 2008, Cicatiello et al. 2004, Castro-Rivera et
al. 2001, Wang et al. 2011, Shang et al. 2000). Since the interaction between
ER and c-fos is likely mediated indirectly by c-jun (Bjornstrom et al. 2005),
further studies were carried out using both ChIP re-ChIP and triple-ChIP assays
to determine if ER regulates SDF-1 via interactions with c-jun/c-fos heterodimer.
Data from both forward and reverse ChIP re-ChIP assays suggested that cells
chronically exposed to cadmium (Cd7 and Cd12) exhibited higher levels of
ER/c-jun complexes on the SDF-1 promoter (Fig. 6C). The increase in ER/cjun interactions further emphasizes the importance of ER and c-jun in regulating
SDF-1 expression, especially in cells chronically exposed to cadmium.
Consistent with these results, c-jun has been shown to regulate SDF-1
expression in other cell types (Florin et al. 2004, Florin et al. 2005). These new
results also mirrored those from our previous study, which had demonstrated that
the ER/c-jun interaction was important in modulating the expression of genes in
response to acute cadmium exposure (Siewit et al. 2010). Interestingly, the
ER/c-jun interaction has also been shown to be important in cells exposed to
arsenic stress (Qi et al. 2004), suggesting this may serve as a common metalresponse mechanism.
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In summary, the results from this study demonstrate for the first time that
chronic cadmium exposure promotes the acquisition of more aggressive cancer
phenotypes (e.g. growth, migration and invasion) by stimulating the expression of
SDF-1, and altering the molecular interactions between ER, c-jun and c-fos.
Additionally, the data in this study suggest that the molecular dynamics of cells
chronically exposed to cadmium are significantly different from cells that are not
exposed to cadmium. We speculate that the molecular interactions of ERα with
other transcription factors, including other members of the AP-1 family and
members of E2F and NFkB families are also affected by chronic cadmium
exposure, and likely in a promoter-specific manner (Marino et al. 2006, Klinge et
al. 2004). Since estrogen receptor is known interact with many coactivators and
corepressors (Shang et al. 2000, Florin et al. 2004, Florin et al. 2005, Marino et
al. 2006, Klinge et al. 2004), it would also be interesting to determine how chronic
cadmium exposure may alter the molecular interactions between ER and its
coregulators in future studies. The results presented in this study offer molecular
insights into how mammary tumors containing significant levels of cadmium can
become more aggressive and underscore the importance of studying the
molecular effects of chronic cadmium exposure in breast carcinogenesis.
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CHAPTER 3
CHRONIC CADMIUM EXPOSURE DISRUPTS CELL-TO-CELL ADHESIONS
BY DOWN-REGULATING E-CADHERIN

3.1 Introduction
As stated in the previous chapter, ce lls exposed to cadmium for prolonged
periods of time have been shown to di splay more aggressive cancer phenot ypes
that include an increased abilit y to grow i n an anchorage-independent fashion
and the capacity to invade surrounding ti

ssue (Benbrahim-Tallaa et al. 2009,

Achanzar et al. 2001). Invasion and

subsequent metastasis require the

detachment of cells from the pri mary tumor site. One way this can be achieved
is through loss of cell adhesion mole cules such as E-cadherin and catenin. Ecadherin is a transmembrane glycoprotein which play s a key role in hemophilic
Ca2+-dependent cell-to-ce ll adhesion (Pearson

and Proz ialeck 2001).

Specifically, E-cadherin associates with actin microfilaments via catenin, a key
protein coordinating cell-to -cell adhesions. Studies have shown

that cadmium

may replace calcium in the E-cadherin ce ll-to-cell junctions, thus disrupting t he
cadherin/catenin complex (Pr ozialeck a nd Niewenhuis 1991,
Lamar 1997), but such studies
cadmium-induced disruption

Prozialeck and

have not demonstrated a link between this
and the development of

invasive/metastatic

phenotypes in breast cancer.
This study aims to understand how ch ronic cadmium exposure contributes
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between E-cadherin and catenin. We provide several lines of evidence that
suggest that prolonged cadmium exposure disrupts the cell-to-cell adhesion
molecules E-cadherin and catenin. Our results demonstrate that MCF7 breast
cancer cells chronically exposed to cadmium have decreased E-cadherin
expression and subsequently a diminished number of E-cadherin/β-catenin
complexes. In short, these results suggest that chronic exposure to heavy metals
like cadmium disrupts inter- and intracellular adhesion protein complexes to
facilitate breast cancer progression by mediating molecular changes that alter the
cancer cells’ ability to migrate and invade (Chapter 2).

3.2 Materials and Methods
Cell Culture
MCF7 cells were obtained from American Type Culture Collection (ATCC,
Manassas, VA). MCF7-Cd was developed by exposing parental MCF7 cells to
10-7 M CdCl2 for over 6 months, and clonal cell lines Cd7 and Cd12 were derived
from this line. Parental MCF7 and MCF7-Cd7 and -Cd12 were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal
Bovine Serum (FBS; Hyclone, Logan, UT) and antibiotics. Both cell lines were
subcultured every 3-4 days.

Western Blot
Cells were lysed in 1% SDS-HEPES buffer and total protein concentration was
normalized using the Bio-Rad Dc Protein Assay kit (Bio-Rad, Hercules, CA).
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Total protein was separated via SDS-polyacrylamide gel electrophoresis and
transferred to polyvinyl difluoride (PVDF) membranes (Millipore, Billerica, MA).
Protein expression was monitored using protein-specific rabbit polyclonal
antibodies: -CDH-1 (Santa Cruz Biotechnology, Santa Cruz, CA), catenin
(Santa Cruz Biotechnology, Santa Cruz, CA), and -GAPDH (Cell Signaling
Technology, Danvers, MA.

Reverse Transcriptase Polymerase Chain Reaction (RT- PCR)
Total RNA was isolated from normal MCF7, MCF7-Cd4, Cd7, and Cd12 using
TRI-Reagent (Zymo Research Corporation, Irvine, CA) and columns from the
Direct-zol RNA MiniPrep kit (Zymo Research) according to manufacturer’s
protocol. Three micrograms (g) of total RNA were used for the reverse
transcription reaction with oligo-dT18 primers and Moloney Murine Leukemia Virus
Reverse Transcriptase (M-MLV RT, Promega, Madison, WI). Gene expression
was monitored using semi-quantitative PCR for 28 cycles. PCR products were
separated by agarose gel electrophoresis and visualized using the Chemi-Doc
gel documentation system (Bio-Rad, Hercules, CA). Gene expression was
quantified by quantitative real-time RT-PCR using the SYBR Green real-time
PCR master mix (SA Biosciences, Valencia, CA). All primers were synthesized
by Integrated DNA Technologies, Inc. (IDT; San Diego, CA). Primers used and
their sequences are as follows:
CDH-1F: CATTCTACACGTAGCAGTGACG
CDH-1R: CTGGAGAACCATTGTCTGTAGC
-cateninF: TACCTCCCAAGTCCTGTATGAG
-cateninR: CTTATTAACCACCACCTGGTCC
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GAPDHF: GAAATCCCATCACCATCTTCCAG
GAPDHR: ATGAGTCCTTCCACGATACCAAAG
Coimmunoprecipitation (CoIP) Assay
MCF7, MCF7-Cd7 and -Cd12 were plated in 10cm plates and harvested 48
hours later. Cells were lysed in 0.5% NP-40 lysis buffer and sonicated threetimes for 30 seconds. Total protein cell lysates were treated with anti-E-cadherin
antibody (Santa Cruz Biotechnology) for 2 hours and then incubated with either
protein A or G agarose beads for 1 hour. Protein complexes were separated by
SDS-PAGE followed by Western blot analysis. Membranes were probed for Ecadherin (Santa Cruz Biotechnology), -catenin (Santa Cruz Biotechnology) or
normal rabbit IgG (Santa Cruz Biotechnology).

Immunofluorescence Microscopy
MCF-7, MCF7-Cd7 and -Cd12 were plated on 6-well plates containing sterile
cover slips. Cells were fixed 24 hours later in 10% formalin. Protein expression
was

analyzed

using

monoclonal

antibodies

to

-catenin

(Santa

Cruz

Biotechnology), polyclonal antibodies to E-cadherin (Cell Signaling Technology),
or polyclonal antibodies to active -catenin (Cell Signaling Technology).
Secondary antibodies conjugated to Alexa-488 (green) and Alexa-647 (red)
(Molecular Probes, Life Technologies, Grand Island, NY) were used to detect
protein expression and images were visualized using a fluorescent microscope
(Leica Microsystems, Inc, Deerfield, IL).
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3.3 Results
Previous data from our lab suggest that MCF7 cells chronically exposed to
cadmium (MCF7-Cd) display increased metastatic phenotypes—including
changes in migration, cell adhesion and invasion—all of which are characteristics
of cancer progression. Other studies have also implicated E-cadherin in many of
these processes. To understand how chronic cadmium exposure affects the
expression of E-cadherin, clonal cell lines (MCF7-Cd7, Cd12) derived from cells
chronically exposed to cadmium were used for expression analysis and
compared to those of parental MCF7 cells. Gene and protein expression levels
were analyzed by semi-quantitative RT-PCR and Western blot, respectively (Fig.
1 A-B). Results shown in Figure 1A suggest that cells chronically exposed to
cadmium (Cd7 and Cd12) express similar levels of E-cadherin at the transcription
level as the parental MCF7 cells. There is also no significant difference in βcatenin gene expression among the cadmium-adapted and parental MCF7 cells.
However, cells chronically exposed to cadmium did express lower levels of Ecadherin at the protein level (Figure 1B). This effect was not uniformly observed
with -catenin, as one cadmium-exposed clone demonstrated a significant
decrease in expression (Cd12) while another showed no appreciable change in
-catenin expression (Cd7) when compared to the parent cell line. To determine
if the cadmium-induced decrease of E-cadherin is specific to only chronic
exposures, we treated parental MCF7 cells with 10 -6 M cadmium chloride (CdCl2)
and compared it to cells treated with 10-7 M estrogen under acute conditions.
Cells were then harvested 0, 1, 2, 4, 8, 12 and 24 hours after treatment, and
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Figure 1: Cells chronically exposed to cadmium express lower protein levels of
E-cadherin. (A) MCF7, MCF7-Cd7 and -Cd12 were plated in 6 well plates and total RNA was
isolated for gene expression analysis using semi-quantitative PCR. (B) Protein expression in
MCF7, Cd7, and Cd12 cells was analyzed by Western blot analysis.
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protein expression was analyzed using Western blot analysis. Results in Figure 2
show that both cadmium and estrogen are able to promote down-regulation of Ecadherin protein expression under acute conditions. In contrast, the expression
of total -catenin was elevated in response to both acute cadmium and estrogen
treatment. Other than the membrane-localized form of -catenin that normally
interacts with E-cadherin to mediate cell-cell interaction, -catenin also exists in a
dephosphorylated or active form that functions as a transcription factor to
regulate gene expression in the nucleus. We also evaluated the levels of active
-catenin and found that— similar to total -catenin levels— the active form was
also increased in response to cadmium and estrogen (Fig. 2). 
Since E-cadherin and -catenin often function in a complex to mediate
cell-cell adhesion, we question whether the cadmium-induced decrease of Ecadherin may alter this interaction. To determine if the interaction between Ecadherin and -catenin are disrupted in cells chronically exposed to cadmium,
cells were collected for co-immunoprecipitation assays. Total cell lysates of both
cadmium-adapted

(Cd7

and

Cd12)

and

parental

MCF7

cells

were

immunoprecipitated with antibodies against E-cadherin. Results in Figure 3 show
a decrease of -catenin protein complexed to E-cadherin in cells chronically
exposed to cadmium (7 and 12) in comparison to the parental MCF7 cells (M).
To verify that fewer E-cadherin/-catenin complexes exist within cells
chronically exposed to cadmium, we also examined the expression of this protein
complex using immunofluorescence microscopy. Results in Figure 4 show that
both parental (MCF7) and cadmium-adapted cells (Cd7 and Cd12) express E-
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Figure 2: Acute cadmium and estrogen exposures promote the down-regulation of
E-cadherin. MCF7 cells were plated in 6-well plates and treated with 10-6 M CdCl2 or 10-7 M
E2. Cells were harvested 0, 1, 2, 4, 8, 12, and 24 hours after treatment for protein expression
analysis by Western blot.
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Figure 3: Chronic cadmium exposure alters E-cadherin/β
β -catenin complex interactions.
MCF7 (M), Cd7 (7) and Cd12 (12) were harvested forco-immunoprecipitation (co-IP) and total
cell lysates were immunoprecipitated with α-E-cadherin. β-catenin/E-cadherin interactions
were analyzed by Western blot analysis.
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cadherin (green) and -catenin (red); however, the distribution of the two proteins
is dramatically different. In parental MCF7 cells, both E-cadherin and -catenin
are primarily co-localized to the plasma membrane (merged- yellow) with low
levels found in the cytoplasm; in Cd7 and Cd12 cells, lower levels of E-cadherin
and -catenin are found in the plasma membrane. The -catenin that is found
near the plasma membrane is not as well-organized as that which is observed in
the parental MCF7 cells. Consistent with these observations, the Cd7 and C12
cells are morphologically different, with individual cells farther apart and
displaying fewer cell-cell interactions in comparison to parental cells (Fig. 4).
As mentioned earlier, in addition to the membrane-localized form of catenin, the active form of -catenin is primarily localized to the nucleus where it
regulates gene expression. To examine how changes in the E-cadherin protein
levels

and

distribution

alter

the

active

form

of

-catenin,

we

used

immunofluorescence to monitor the localization of the active form of -catenin in
the various cells. Results in Figure 5 show that cadmium-adapted cells (Cd7 and
Cd12) display elevated levels of active -catenin (green) in the nucleus in
comparison to parental MCF-7 cells, suggesting that changes in expression of
genes associated with chronic cadmium exposure may be associated with the
redistribution of -catenin from the plasma membrane to the nucleus.
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Figure 4: Prolonged cadmium exposure disrupts E-cadherin/β
β -catenin complex. Protein localization of E-cadherin and β-catenin was
analyzed in MCF-7, Cd7 and Cd12 cells using immunofluorescence microscopy. E-cadherin (FITC), β-catenin (Texas Red), and nucleus (DAPI).
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Figure 5: Active β -catenin localizes in the nucleus of prolonged cadmium exposed cells.
Protein localization of active β-catenin was analyzed in MCF-7, Cd7 and Cd12 cells using
immunofluorescence microscopy. Active β-catenin (FITC) and nucleus (DAPI).
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3.4 Discussion
E-cadherin is known as a tumor suppressor protein and is used as a
prognostic marker for breast cancer (Heimann et al. 2000, Baranwal and Alahari
2009). Results from this study show that cadmium disrupts cell-to-cell adhesion
by down-regulating E-cadherin at the protein level (Fig. 1). Down-regulation of Ecadherin has been associated with more aggressive breast cancers and poor
prognosis (Mohammadizadeh et al. 2009, Oka et al. 1993).

Consistent with a

recent study by Chakraborty et al. which showed that acute treatments of
cadmium were able to disrupt E-cadherin/-catenin junction complex and
degrade E-cadherin in kidney tubule cells (Chakraborty et al. 2010), we
demonstrated that both acute cadmium and estrogen exposure lead to the downregulation of E-cadherin protein (Fig. 2). Several studies have shown that
estrogen can induce the down-regulation and degradation of E-cadherin and the
process has been shown to be mediated through ER (Oesterreich et al. 2003,
Cardamone et al. 2009, Potter et al. 1996, Park et al. 2008). Since cadmium
functions as a metalloestrogen, the observation that both acute and chronic
cadmium exposures likewise down-regulate E-cadherin is not surprising.
Most importantly, we showed that chronic cadmium exposure promotes the
down-regulation of E-cadherin and significantly alters the interaction of Ecadherin with -catenin. Using co-immunoprecipitation assays, results show that
indeed fewer -catenin molecules were complexed with E-cadherin in cadmium
cells (Cd7 and Cd12) in comparison to the parental MCF7 cells. Once E-cadherin
and -catenin are no longer complexed, we speculate that increased amounts of
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-catenin may translocate to the nucleus and cross-talk with other transcription
factors to modulate expression of genes (Chakraborty et al. 2010, Lin et al. 2000,
He et al. 1998, Li et al. 1999, Mann et al. 1999), including c-myc and cyclin D1,
which been shown to be elevated in cadmium exposed cells (Siewit et al. 2010,
Chakraborty et al. 2010, Benbrahim-Tallaa et al. 2009). Immunofluorescence
microscopy supported this speculation by revealing altered distribution patterns
of E-cadherin and -catenin in cells chronically exposed to cadmium. Lower
levels of E-cadherin and -catenin were found in the plasma membrane of
cadmium-treated cells, and there were elevated levels of active -catenin in the
nucleus. We contend that -catenin, once freed from the E-cadherin adhesion
complex, can localize into the nucleus where it regulates transcription by
interacting with transcription factors such as the T-cell factor-4 (TCF-4) or
lymphoid enhancer factor-1 (LEF-1), thus activating target genes and the Wnt
signaling pathway (Lin et al. 2000, Chakraborty et al 2010).
In short, we propose that results from this study demonstrate that prolonged
cadmium exposure disrupts cell-cell adhesion by down-regulating E-cadherin
expression and relocating active -catenin to the nucleus. This in turn mediates
the increased invasive and metastatic properties associated with chronic
exposures to cadmium.

70

3.5 References
Achanzar WE, Diwan BA, Liu J, Quader ST, Webber MM, Waalkes MP (2001)
Cadmium-induced malignant transformation of human prostate epithelial
cells. Cancer Res. 61: 455-458.
Baranwal S, Alahari SK (2009) Molecular mechanisms controlling E-cadherin
expression in breast cancer. Biochem Biophys Res Commun. 384: 6-11.
Benbrahim-Tallaa L, Tokar EJ, Diwan BA, Dill AL, Coppin JF, Waalkes MP
(2009) Cadmium Malignantly Transforms Normal Human Breast Epithelial
Cells into a Basal-like Phenotype. Environ Health Perspect. 117: 18471852.
Cardamone MD, Bardella C, Gutierrez A, Di Croce LD, Rosenfeld MG, Di Renzo
MF, De Bortoli M (2009) ERalpha as ligand-independent activator of CDH1 regulates determination and maintenance of epithelial morphology in
breast cancer cells. Proc Natl Acad Sci U S A. 106: 7420-7425.
Chakraborty PK, Lee WK, Molitor M, Wolff NA, Thevenod F (2010) Cadmium
induces Wnt signaling to upregulate proliferation and survival genes in
sub-confluent kidney proximal tubule cells. Mol Cancer. 9:102.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ,
Vogelstein B, Kinzler KW (1998) Identification of c-MYC as a target of the
APC pathway. Science. 281: 1509-1512.
Heimann R, Lan F, McBride R, Hellman S (2000) Separating favorable from
unfavorable prognostic markers in breast cancer: the role of E-cadherin.
Cancer Res. 60: 298-304.
Li L, Yuan H, Xie W, Mao J, Caruso AM, McMahon A, Sussman DJ, Wu D (1999)
Disheveled proteins lead to two signaling pathways . Regulation of LEF-1
and c-Jun N-terminal kinase in mammalian cells. J Biol Chem, 274: 129134.
Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC
(2000) Beta-catenin, a novel prognostic marker for breast cancer: its roles
in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S
A. 97: 4262-4266.
Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF,
Moyer MP, Riecken EO, Buhr HJ, Hanski C (1999) Target genes of betacatenin-T-cell-factor/lymphoid-enhancer-factor
signaling
in
human
colorectal carcinomas. Proc Natl Acad Sci U S A. 96: 1603-1608.

71

Mohammadizadeh F, Ghasemibasir H, Rajabi P, Naimi A, Eftekhari A., Mesbah
A (2009) Correlation of E-cadherin expression and routine
immunohistochemistry panel in breast invasive ductal carcinoma. Cancer
Biomark. 5: 1-8.
Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell DL,
Behrens J, Lee AV (2003) Estrogen-mediated down-regulation of Ecadherin in breast cancer cells. Cancer Res. 63: 5203-5208.
Oka H, Shiozaki H, Kobayashi K, Inoue K, Tahara H, Kobayashi T, Takatsuka Y,
Matsuyoshi N, Hirano S, Takeichi M, et al (1993) Expression of E-cadherin
cell adhesion molecules in human breast cancer tissues and its
relationship to metastasis. Cancer Res. 53: 1696-1701.
Park SH, Cheung LW, Wong AS, Leung PC (2008) Estrogen regulates Snail and
Slug in the down-regulation of E-cadherin and induces metastatic potential
of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol.
22: 2085-2098.
Pearson CA, Prozialeck WC (2001) E-cadherin, β-catenin and cadmium
carcinogenesis. Med Hypotheses. 56: 573-581.
Potter SW, Gaza G, Morris JE (1996) Estradiol induces E-cadherin degradation
in mouse uterine epithelium during the estrous cycle and early pregnancy.
J Cell Physiol. 169: 1-14.
Prozialeck WC, Lamar PC (1997) Cadmium (Cd2+) disrupts E-cadherindependent cell-cell junctions in MDCK cells. In Vitro Cell Dev Biol Anim.
33: 515-526.
Prozialeck WC, Niewenhuis RJ (1991) Cadmium disrupts Ca2+-dependent cellcell junctions and alters pattern of E-cadherin immunofluorescence in
LLC-PK cells. Biochem Biophys Res Commun. 181: 1118-1124.
Siewit CL, Gengler B, Vegas E, Puckett R, Louie MC (2010) Cadmium promotes
breast cancer cell proliferation by potentiating the interaction between
ERalpha and c-Jun. Mol Endocrinol 24: 981-992.

72

CHAPTER 4
CONCLUSION

Our research has provided an original contribution to the field of breast
cancer

progression.

Specifically,

we

have

demonstrated

two

possible

mechanisms of cadmium carcinogenesis (Chapters 2 and 3). Unlike most studies
that have focused on the effects of acute cadmium exposure on breast cancer,
our study largely focused on the effects of chronic cadmium exposure on breast
cancer progression. In order to begin to understand the effects of chronic
cadmium exposure on breast cancer progression, we developed several MCF7
clonal cell lines that were exposed to low concentrations of cadmium for a
prolonged period of time (6 months). Using this model system, we evaluated the
impacts of this exposure on breast cancer progression. Results from this work
not only demonstrated that prolonged exposure to cadmium increases cell
proliferation through the activation of ER— as seen in most acute studies— but
also results in the acquisition of more aggressive cancer phenotypes.
Our findings in Chapter 2 show that cells chronically exposed to cadmium
display an increased ability to proliferate, migrate and invade when compared to
the parental MCF7 cell line. Further analysis revealed that chronic cadmium
exposure stimulated cells to express higher levels of SDF-1, a chemokine often
associated with tumor invasion and metastasis. We also provided several lines
of evidence suggesting that the expression of SDF-1 is not only dependent on
the levels of ER, but also on its interaction with c-jun/c-fos heterodimers. The
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findings presented here suggest that chronic cadmium exposure promotes
migration and invasion by altering the molecular interactions of ER, c-jun and cfos and subsequent transcriptional machinery to up-regulate SDF-1 expression.
While SDF-1 is an important contributor of metastasis, there are likely
other factors that participate in this process and facilitate the transformation to a
more malignant phenotype. In Chapter 3, we revealed that chronic exposure to
cadmium also alters the expression of two crucial cell-cell adhesion molecules,
E-cadherin and -catenin. More specifically, cells chronically exposed to
cadmium expresses lower levels of E-cadherin at the protein level. Since no
changes are observed at the transcriptional level, this suggests that cadmium
exposure promotes the down-regulation of the E-cadherin protein. The
consequence of losing E-cadherin is two fold—(1) decrease in cell-cell adhesion
and (2) redistribution of -catenin into the nucleus where it alters gene
expression to stimulate breast cancer progression.
In summary, the research presented here has demonstrated that chronic
cadmium exposure facilitates the progression of breast cancer by mediating
molecular changes that alter cancer cells’ ability to migrate and invade. While
this work has made significant advancements in the understanding of how
environmental

contaminants

such

as

cadmium

promote

breast

cancer

progression, it also warrants the need for further research in this area to help us
truly understand cadmium carcinogenesis.
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